Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Cognitive impairment is prevalent in individuals with chronic kidney disease (CKD), but its effects on health outcomes remain unclear. While cognitive impairment can affect self-management, its role in CKD has been insufficiently explored. This systematic review aimed to examine the association between cognitive impairment and health outcomes or self-management ability among persons with CKD.
Methods: Searches were performed in June 2024 on Embase, MEDLINE, CINAHL, PsycINFO, Web of Science, PubMed and grey literature databases for longitudinal or cross-sectional studies examining associations between cognitive impairment (using any validated measure) and health outcomes or ability to self-manage in adults with CKD not on kidney replacement therapy. Health outcomes included mortality, kidney disease progression, hospitalization and healthcare utilization, cardiovascular and cerebrovascular events, and health-related quality of life (HRQoL). Risk of bias was assessed using the ROBINS-E ('Risk of bias in non-randomized studies of exposure') tool.
Results: Fourteen studies were included. Cognitive impairment was associated with increased all-cause and cardiovascular mortality, higher risk of cardiac arrhythmia, stroke and transient ischaemic attack, lower HRQoL, and higher healthcare utilization. Mixed results were seen in studies examining the association between cognitive impairment and kidney disease progression. No studies with self-management measures as an outcome were identified.
Conclusions: Cognitive impairment is associated with poor health outcomes in persons with CKD, although evidence was limited for some outcomes. No causal link could be established due to potential residual confounding by frailty or shared comorbidities. Further research is required to explore potential causal pathways and the role of cognitive impairment in CKD self-management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257935 | PMC |
| http://dx.doi.org/10.1093/ckj/sfaf150 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prodromal Lewy Body Symptoms and α-Synuclein Seeding in Idiopathic Olfactory Dysfunction.
Mov Disord Clin Pract
September 2025
Department of Neurology, Danish Dementia Research Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Background: Early identification of pathological α-synuclein deposition (αSynD) may improve understanding of Lewy body disorder (LBD) progression and enable timely disease-modifying treatments.
Objectives: We investigated αSynD using a seed amplification assay and assessed prodromal LBD symptoms in individuals with idiopathic olfactory dysfunction (iOD).
Methods: In this cross-sectional, case-control study, we included iOD participants and normosmic healthy controls (HC) aged 55 to 75 years without diagnoses of dementia with Lewy bodies, Parkinson's disease (PD), or other major neurological disorders.
Investigating the impact of hyperbilirubinemia on cognitive dysfunction in adult zebrafish: an in vivo model.
Korean J Anesthesiol
September 2025
Department of Anesthesiology and Pain Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15588, the Republic of Korea.
Background: Despite the well-known effects of elevated bilirubin in neonates, its neurotoxic potential in adults remains uncertain. In perioperative and hepatic disease contexts, transient bilirubin elevations are common; however, their direct contribution to cognitive dysfunction has not been clearly established. This study aimed to determine whether transient bilirubin elevation alone can impair cognition and disrupt blood-brain barrier (BBB) function in adult zebrafish, and to compare these effects with those of liver injury.
View Article and Find Full Text PDFAntibody Therapies for Alzheimer's Disease: A New Strategy for Targeted Therapy and Blood-Brain Barrier Delivery.
ACS Chem Neurosci
September 2025
Institute of Cell Engineering, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21215, United States.
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive impairment and neuronal loss, with pathological hallmarks including Aβ plaque deposition and tau tangles. At present, the early diagnosis and treatment of AD still face great challenges, such as limited diagnostic methods, difficulty in blood-brain barrier (BBB) penetration, complex disease mechanisms, and lack of highly effective targeted therapies. Antibody drugs have shown broad prospects in the field of AD due to their high specificity, engineering and multifunctional therapeutic potential, include targeted Aβ clearance, tau pathological regulation, imaging probes, and blood biomarkers.
View Article and Find Full Text PDFPlanning care for nursing-home residents: cognitive impairment, functional independence, and accommodation services in nursing homes in the city of Zagreb.
Croat Med J
August 2025
Nada Tomasović Mrčela, Department of Public Health Gerontology, Andrija Štampar Teaching Institute of Public Health, Mirogojska cesta 16, 10000 Zagreb, Croatia,
Aim: To assess whether the Mini-Mental State Examination, second edition (MMSE-2), scores were associated with the category of functional independence of nursing-home residents and the level of accommodation services they received.
Methods: This cross-sectional study enrolled 248 participants older than 65 residing in five county-owned nursing homes in the city of Zagreb from 2017 to 2019. Cognitive status was assessed with the standard version of the MMSE-2, and the level of functional independence with the modified Barthel scale index.
Network Pharmacology of miR-146a-5p as a Potential Anti-Inflammatory Agent in Preventing Alzheimer's Disease.
Curr Alzheimer Res
September 2025
School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, 47500 Subang Jaya, Selangor, Malaysia.
Introduction: Alzheimer's disease is expressed as chronic neuroinflammation in the brain, which results in neuronal dysfunction, aberrant protein folding, and declining cognitive abilities. miR-146a-5p is a potent anti-inflammatory agent that can be used to treat several inflammatory diseases, as well as promote wound healing. Our research aimed to utilize network pharmacology to elucidate the therapeutic potential of miR-146a-5p in treating Alzheimer's disease using a biocomputational approach.
View Article and Find Full Text PDF